{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:16:00Z","timestamp":1779387360529,"version":"3.53.1"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>This review summarizes contemporary management of Classic Hodgkin Lymphoma in special clinical situations, with a focus on integrating primary clinical trial and observational data to inform individualized treatment decisions. The emphasis is on practical, evidence-based recommendations rather than exhaustive coverage of all regimens.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000829","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:30Z","timestamp":1779386430000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Management of Classic Hodgkin Lymphoma in Special Clinical Situations"],"prefix":"10.1097","volume":"32","author":[{"given":"Thomas","family":"Lucido","sequence":"first","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sawicki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5068-9040","authenticated-orcid":false,"given":"Joanna M.","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"R2-20260521","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"R3-20260521","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"R5-20260521","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"R6-20260521","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"key":"R7-20260521","first-page":"868","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma (H10 trial)","volume":"18","author":"Andr\u00e9","year":"2017","journal-title":"Lancet Oncol"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"R9-20260521","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"R10-20260521","first-page":"203","article-title":"Nivolumab plus AVD versus brentuximab vedotin plus AVD for advanced-stage Hodgkin lymphoma (SWOG S1826)","volume":"390","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"R12-20260521","first-page":"2702","article-title":"Nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplantation: full results from CheckMate 205","volume":"35","author":"Ansell","year":"2017","journal-title":"J Clin Oncol"},{"key":"R13-20260521","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed or refractory classical Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3324\/haematol.2015.136408","article-title":"Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial","volume":"101","author":"Sibon","year":"2016","journal-title":"Haematologica"},{"key":"R15-20260521","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"R16-20260521","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology: developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in patients aged \u226560 years with Hodgkin lymphoma","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.18947","article-title":"\u2018ACOPP\u2019 chemotherapy for older and less fit patients with Hodgkin lymphoma: a multicentre, retrospective study","volume":"202","author":"Wilson","year":"2023","journal-title":"Br J Haematol"},{"key":"R21-20260521","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"R22-20260521","first-page":"15","article-title":"Enalapril for the prevention of anthracycline-induced cardiotoxicity in patients with breast cancer and non-Hodgkin lymphoma (PROACT): a randomized clinical trial","volume":"6","author":"Austin","year":"2024","journal-title":"JACC CardioOncol"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Effect of candesartan and metoprolol on myocardial injury during adjuvant breast cancer therapy: extended follow-up of the PRADA trial","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"R25-20260521","first-page":"68","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity: a systematic review and meta-analysis. JACC CardioOncol","volume":"1","author":"Macedo","year":"2019"},{"key":"R26-20260521","first-page":"90","article-title":"Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials","volume":"11","author":"Cavalli","year":"2025","journal-title":"Cardiooncology"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R29-20260521","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"R30-20260521","first-page":"789","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"65","author":"Cutter","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R31-20260521","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"R32-20260521","first-page":"2762","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"128","author":"Martin","year":"2005","journal-title":"Chest"},{"key":"R33-20260521","first-page":"1035","article-title":"Brentuximab vedotin plus chemotherapy in early-stage unfavorable Hodgkin lymphoma: results of the BREACH trial","volume":"41","author":"Advani","year":"2023","journal-title":"J Clin Oncol"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"R35-20260521","first-page":"1961","article-title":"De-escalation of bleomycin after negative interim PET in early-stage Hodgkin lymphoma: a retrospective analysis","volume":"98","author":"Yang","year":"2019","journal-title":"Ann Hematol"},{"key":"R36-20260521","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with early-stage favorable Hodgkin lymphoma (HD13): a randomized, open-label, phase 3 trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"R37-20260521","first-page":"935","article-title":"Pulmonary function impairment following treatment for Hodgkin lymphoma","volume":"21","author":"van Leeuwen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3 suppl","key":"R38-20260521","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R39-20260521","first-page":"1169","article-title":"Brentuximab vedotin in patients with renal dysfunction, including those receiving dialysis: a case series","volume":"95","author":"Ogura","year":"2016","journal-title":"Ann Hematol"},{"key":"R40-20260521","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R41-20260521","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"R42-20260521","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy","volume":"13","author":"Velasco","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R43-20260521","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R44-20260521","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplantation: extended follow-up of the CheckMate 205 study","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"R45-20260521","first-page":"227","article-title":"Long-term follow-up of nivolumab in relapsed or refractory classical Hodgkin lymphoma","volume":"138","author":"Ansell","year":"2021","journal-title":"Blood"},{"key":"R46-20260521","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"R47-20260521","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti\u2013PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"R48-20260521","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death\u20131 pathway inhibitors among patients with non\u2013small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"R49-20260521","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti\u2013programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"R50-20260521","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"},{"key":"R51-20260521","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor\u2013related myasthenia gravis: single-center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R52-20260521","doi-asserted-by":"crossref","first-page":"e2513727","DOI":"10.1001\/jamanetworkopen.2025.13727","article-title":"Immune checkpoint inhibitors in patients with preexisting autoimmune neurologic disorders","volume":"8","author":"Fletcher","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R53-20260521","first-page":"109","article-title":"Radiotherapy during pregnancy for clinical stages IA\u2013IIA Hodgkin\u2019s disease","volume":"36","author":"Woo","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R54-20260521","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(05)70169-8","article-title":"Radiotherapy during pregnancy: fact and fiction","volume":"6","author":"Kal","year":"2005","journal-title":"Lancet Oncol"},{"key":"R55-20260521","first-page":"110021","article-title":"Fetal dose from involved-site radiotherapy for lymphoma during pregnancy: a phantom-based dosimetric study using modern techniques","volume":"190","author":"Smeets","year":"2025","journal-title":"Radiother Oncol"},{"key":"R56-20260521","first-page":"2225","article-title":"Treatment of Hodgkin lymphoma during pregnancy","volume":"51","author":"Avil\u00e9s","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R57-20260521","first-page":"430","article-title":"Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero","volume":"91","author":"Avil\u00e9s","year":"2001","journal-title":"Cancer"},{"key":"R58-20260521","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamaoncol.2016.1396","article-title":"Maternal and fetal outcomes after therapy for Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy","volume":"2","author":"Pinnix","year":"2016","journal-title":"JAMA Oncol"},{"key":"R59-20260521","first-page":"4132","article-title":"Hodgkin lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival","volume":"30","author":"Evens","year":"2012","journal-title":"J Clin Oncol"},{"key":"R60-20260521","first-page":"e22","article-title":"Nivolumab exposure during pregnancy in a patient with relapsed Hodgkin lymphoma","volume":"198","author":"Burotto","year":"2022","journal-title":"Br J Haematol"},{"key":"R61-20260521","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"key":"R62-20260521","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J Clin Oncol"},{"key":"R63-20260521","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/S2352-3026(23)00157-6","article-title":"Brentuximab vedotin with AVD for stage II\u2013IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, multicenter phase 1\/2 trial","volume":"10","author":"Rubinstein","year":"2023","journal-title":"Lancet Haematol"},{"key":"R64-20260521","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clml.2024.03.011","article-title":"Real-world multicenter study of PD-1 blockade in HIV-associated classical Hodgkin lymphoma across the United States","volume":"24","author":"Lurain","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R65-20260521","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/cid\/ciu174","article-title":"Management of HIV infection in patients with cancer receiving chemotherapy","volume":"59","author":"Torres","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R66-20260521","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/1097-0142(20000801)89:3<680::AID-CNCR25>3.0.CO;2-W","article-title":"High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy","volume":"89","author":"Molina","year":"2000","journal-title":"Cancer"},{"key":"R67-20260521","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3390\/v17111436","article-title":"Real-world effectiveness of antiviral prophylaxis for preventing hepatitis B virus (HBV) reactivation in patients undergoing immunosuppressive therapy","volume":"17","author":"Yilmaz Nakir","year":"2025","journal-title":"Viruses"},{"key":"R68-20260521","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.21037\/atm-20-5964","article-title":"Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis","volume":"8","author":"Ye","year":"2020","journal-title":"Ann Transl Med"},{"key":"R69-20260521","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:38Z","timestamp":1779386438000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000829","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2026-01-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}